Lysogene appointed Dr. Peter Lichtlen to the Board of Directors, as a non-executive, independent member effective from April 1, 2018. Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc. until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology. It is also announced that Dr. Olivier Danos has resigned from the Board effective April 1, 2018.